Browse by Glasgow Author (original) (raw)

Number of items: 143.

2026

Ono, R. et al. (2026)Lactate dehydrogenase and outcomes in patients with HF and reduced ejection fraction. JACC: Heart Failure, (doi: 10.1016/j.jchf.2025.102900) (In Press)

Campbell, R. T. et al. (2026)SUBCUT HF II: rationale and design of a multicentre randomized controlled trial of SUBCUTaneous furosemide to support early discharge in patients admitted to hospital due to Heart Failure. European Journal of Heart Failure, (doi: 10.1093/ejhf/xuaf018) (Early Online Publication)

Razzaq, U. B. et al. (2026)Post-COVID-19 era heart failure diagnosis and outcomes: adherence to National Institute for Health and Care Excellence Guidelines. Open Heart, 13(1), e003785. (doi: 10.1136/openhrt-2025-003785) (PMID:41513295)

2025

Matsumoto, S. et al. (2025)Obesity, aldosterone, and natriuretic peptide in patients with heart failure and reduced ejection fraction. Cardiovascular Research, cvaf235. (doi: 10.1093/cvr/cvaf235) (PMID:41248675) (Accepted for Publication)

Butt, J. H. et al. (2025)Dapagliflozin, heart failure, and duration of diabetes: a patient-level pooled meta-analysis of DAPA-HF and DELIVER. JACC: Heart Failure, 13(10), 102630. (doi: 10.1016/j.jchf.2025.102630) (PMID:40884985)

Ismahel, Hassan ORCID: https://orcid.org/0000-0002-1288-9498 and Docherty, Kieran F. ORCID: https://orcid.org/0000-0002-5446-9969(2025)The role of finerenone in heart failure. Trends in Cardiovascular Medicine, 35(7), pp. 468-476. (doi: 10.1016/j.tcm.2025.05.002) (PMID:40383455)

Bøgh-Sørensen, Sofie, Campbell, Ross T. ORCID: https://orcid.org/0000-0002-0050-2129, Claggett, Brian L, Lewis, Eldrin F, Docherty, Kieran F. ORCID: https://orcid.org/0000-0002-5446-9969, Lee, Matthew M.Y. ORCID: https://orcid.org/0000-0001-9213-2067, Lindner, Moritz, Biering-Sørensen, Tor, Solomon, Scott D. and Platz, Elke(2025)The intersection of obesity and acute heart failure: cardiac structure and function and congestion across BMI categories. European Heart Journal: Acute Cardiovascular Care, 14(9), pp. 540-551. (doi: 10.1093/ehjacc/zuaf067) (PMID:40294203) (PMCID:PMC12502657)

Chimura, M. et al. (2025)Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trial. European Heart Journal, (doi: 10.1093/eurheartj/ehaf706) (PMID:40886161) (Early Online Publication)

Docherty, K. et al. (2025)Benefit of early initiation of disease-modifying therapy in community-based patients with suspected heart failure. European Heart Journal, (doi: 10.1093/eurheartj/ehaf675) (PMID:40879671) (Early Online Publication)

Campbell, R. et al. (2025)Artificial intelligence fully automated analysis of handheld echocardiography in real-world patients with suspected heart failure. European Journal of Heart Failure, (doi: 10.1002/ejhf.3783) (PMID:40702880) (Early Online Publication)

Docherty, K. F. et al. (2025)Interleukin-6 in heart failure with reduced ejection fraction and the effect of dapagliflozin : an exploratory analysis of the dapagliflozin and prevention of adverse outcomes in heart failure trial. JACC: Heart Failure, 13(7), 102393. (doi: 10.1016/j.jchf.2024.12.012) (PMID:40088234)

Kondo, T. et al. (2025)Effects of sacubitril/valsartan according to natriuretic peptide levels in patients enrolled in PARADIGM-HF and PARAGON-HF. JACC: Heart Failure, 13(6), pp. 927-939. (doi: 10.1016/j.jchf.2024.12.010) (PMID:40088233)

McDowell, K. et al. (2025)Finerenone for heart failure and risk estimated by the PREDICT-HFpEF model. JAMA Cardiology, 10(6), pp. 535-544. (doi: 10.1001/jamacardio.2025.0025) (PMID:40042880)

Chimura, M. et al. (2025)Anaemia in patients with heart failure and mildly reduced or preserved ejection fraction: a prespecified analysis of the FINEARTS ‐ HF trial. European Journal of Heart Failure, (doi: 10.1002/ejhf.3682) (PMID:40377177) (Early Online Publication)

Docherty, Kieran F. ORCID: https://orcid.org/0000-0002-5446-9969(2025)SGLT2 inhibitors in heart failure: iron mobilization at the heart of the matter. Journal of the American College of Cardiology, 85(18), pp. 1771-1773. (doi: 10.1016/j.jacc.2025.03.532) (PMID:40335253)

Docherty, Kieran F. ORCID: https://orcid.org/0000-0002-5446-9969, Shen, Li and McMurray, John J.V. ORCID: https://orcid.org/0000-0002-6317-3975(2025)Advocating for better care of patients with heart failure. European Heart Journal, (doi: 10.1093/eurheartj/ehaf224) (PMID:40271932) (Early Online Publication)

Docherty, K. F. et al. (2025)Wearable accelerometer-derived measures of physical activity in heart failure: insights from the DETERMINE trials. Journal of Cardiac Failure, 31(4), pp. 689-703. (doi: 10.1016/j.cardfail.2024.10.439) (PMID:39603408)

Carberry, J. et al. (2025)Empagliflozin to prevent worsening of left ventricular volumes and systolic function after myocardial infarction (EMPRESS-MI). European Journal of Heart Failure, 27(3), pp. 566-576. (doi: 10.1002/ejhf.3560) (PMID:39675781) (PMCID:PMC11955320)

Yang, M. et al. (2025)EuroQol 5-Dimension questionnaire in heart failure with reduced, mildly reduced, and preserved ejection fraction. JACC: Heart Failure, 13(2), pp. 277-292. (doi: 10.1016/j.jchf.2024.10.020)

Osmanska, J. et al. (2025)Cardiovascular magnetic resonance-estimated pulmonary capillary wedge pressure, congestion markers, and effect of empagliflozin in patients with heart failure with reduced ejection fraction and dysglycaemia (SUGAR-DM-HF). European Journal of Heart Failure, (doi: 10.1002/ejhf.3570) (PMID:39792133) (Early Online Publication)

Docherty, K. F. et al. (2025)Efficacy and safety of finerenone across the ejection fraction spectrum in heart failure with mildly reduced or preserved ejection fraction: a prespecified analysis of the FINEARTS-HF trial. Circulation, 151(1), pp. 45-58. (doi: 10.1161/CIRCULATIONAHA.124.072011) (PMID:39342512) (PMCID:PMC11670913)

Osmanska, Joanna, Petrie, Mark C. ORCID: https://orcid.org/0000-0002-6333-9496, Docherty, Kieran F. ORCID: https://orcid.org/0000-0002-5446-9969, Lee, Matthew M.Y. ORCID: https://orcid.org/0000-0001-9213-2067, McMurray, John J.V. ORCID: https://orcid.org/0000-0002-6317-3975 and Campbell, Ross ORCID: https://orcid.org/0000-0002-0050-2129(2025)Subcutaneous furosemide in heart failure: a systematic review. European Heart Journal: Cardiovascular Pharmacotherapy, 11(1), pp. 94-104. (doi: 10.1093/ehjcvp/pvae083) (PMID:39520561) (PMCID:PMC11805693)

2024

Kondo, Toru, Henderson, Alasdair D. ORCID: https://orcid.org/0000-0002-8903-4906, Docherty, Kieran F. ORCID: https://orcid.org/0000-0002-5446-9969, Jhund, Pardeep S. ORCID: https://orcid.org/0000-0003-4306-5317, Vaduganathan, Muthiah, Solomon, Scott D. and McMurray, John J.V. ORCID: https://orcid.org/0000-0002-6317-3975(2024)Why have we not been able to demonstrate reduced mortality in patients with HFmrEF/HFpEF? Journal of the American College of Cardiology, 84(22), pp. 2233-2240. (doi: 10.1016/j.jacc.2024.08.033) (PMID:39217560)

Butt, Jawad H., Shen, Li, Inzucchi, Silvio E., Docherty, Kieran F. ORCID: https://orcid.org/0000-0002-5446-9969, Jhund, Pardeep S. ORCID: https://orcid.org/0000-0003-4306-5317, Martinez, Felipe A., Sabatine, Marc S., Vaduganathan, Muthiah, Solomon, Scott D. and McMurray, John J.V. ORCID: https://orcid.org/0000-0002-6317-3975(2024)Dapagliflozin in heart failure, type 2 diabetes, and neuropathy. JACC: Heart Failure, 12(11), pp. 1946-1948. (doi: 10.1016/j.jchf.2024.07.017) (PMID:39269393)

Doherty, Daniel J., Abdin, Amr and Docherty, Kieran F. ORCID: https://orcid.org/0000-0002-5446-9969(2024)Heart failure medical therapy in the last years of life: prognosis and practicalities. European Journal of Heart Failure, 26(11), pp. 2451-2452. (doi: 10.1002/ejhf.3450) (PMID:39225181)

Docherty, K. F. et al. (2024)Effect of dapagliflozin on accelerometer-based measures of physical activity in patients with heart failure: an analysis of the DETERMINE trials. Circulation: Heart Failure, 17(10), e012349. (doi: 10.1161/CIRCHEARTFAILURE.124.012349) (PMID:39212948) (PMCID:PMC11472896)

Butt, J. et al. (2024)Dapagliflozin and timing of prior heart failure hospitalization a patient-level meta-analysis of DAPA-HF and DELIVER. JACC: Heart Failure, 12(9), pp. 1586-1599. (doi: 10.1016/j.jchf.2024.01.018) (PMID:38573262)

Ryan, M. et al. (2024)Effect of PCI on health status in ischemic left ventricular dysfunction: insights from REVIVED-BCIS2. JACC: Heart Failure, 12(9), pp. 1553-1562. (doi: 10.1016/j.jchf.2024.03.010) (PMID:38727649)

Cameron, A. et al. (2024)Natriuretic peptides to classify risk of atrial fibrillation detection after stroke: analysis of the BIOSIGNAL and PRECISE cohort studies. Neurology, 103(3), e209625. (doi: 10.1212/WNL.0000000000209625) (PMID:38950311) (PMCID:PMC11226326)

Carberry, J. et al. (2024)Empagliflozin to prevent progressive adverse remodelling after myocardial infarction (EMPRESS-MI): rationale and design. ESC Heart Failure, 11(4), pp. 2001-2012. (doi: 10.1002/ehf2.14830) (PMID:38715187) (PMCID:PMC11287338)

Docherty, Kieran Francis ORCID: https://orcid.org/0000-0002-5446-9969, McMurray, John J.V. ORCID: https://orcid.org/0000-0002-6317-3975, Kalra, Paul, Cleland, John G.F. ORCID: https://orcid.org/0000-0002-1471-7016, Lang, Ninian N. ORCID: https://orcid.org/0000-0001-8441-6887, Petrie, Mark C. ORCID: https://orcid.org/0000-0002-6333-9496, Robertson, Michele and Ford, Ian ORCID: https://orcid.org/0000-0001-5927-1823(2024)Intravenous iron and SGLT2 inhibitors in iron-deficient patients with heart failure and reduced ejection fraction. ESC Heart Failure, 11(4), pp. 1875-1879. (doi: 10.1002/ehf2.14742) (PMID:38549192) (PMCID:PMC11287326)

Carberry, Jaclyn, Marquis-Gravel, Guillaume, O’Meara, Eileen and Docherty, Kieran F. ORCID: https://orcid.org/0000-0002-5446-9969(2024)Where are we with treatment and prevention of heart failure in patients post–myocardial infarction? JACC: Heart Failure, 12(7), pp. 1157-1165. (doi: 10.1016/j.jchf.2024.04.025) (PMID:38878010)

Espersen, C. et al. (2024)Predictors of heart failure readmission and all-cause mortality in patients with acute heart failure. International Journal of Cardiology, 406, 132036. (doi: 10.1016/j.ijcard.2024.132036) (PMID:38599465)

Yang, M. et al. (2024)Dapagliflozin and quality of life measured using the EuroQol 5-Dimension questionnaire in patients with HFrEF and HFmrEF/HFpEF. European Journal of Heart Failure, 26(7), pp. 1524-1538. (doi: 10.1002/ejhf.3263) (PMID:38700986)

Traub, Jan, Docherty, Kieran F. ORCID: https://orcid.org/0000-0002-5446-9969 and Frey, Anna(2024)The link between heart failure and neurodegeneration insights from circulating biomarkers. JACC: Heart Failure, 12(6), pp. 1086-1088. (doi: 10.1016/j.jchf.2024.04.008) (PMID:38839152)

Kondo, T. et al. (2024)Dapagliflozin and days of full health lost through death, hospitalization, and impaired well-being in DAPA-HF. Journal of the American College of Cardiology, 83(20), pp. 1973-1986. (doi: 10.1016/j.jacc.2024.03.385) (PMID:38537918)

Lassen, M. C. H. et al. (2024)Effect of dapagliflozin in patients with diabetes and heart failure with mildly reduced or preserved ejection fraction according to background glucose‐lowering therapy: a pre‐specified analysis of the DELIVER trial. European Journal of Heart Failure, 26(7), pp. 1539-1548. (doi: 10.1002/ejhf.3269) (PMID:38745498)

McDowell, K. et al. (2024)Prognostic models for mortality and morbidity in heart failure with preserved ejection fraction. JAMA Cardiology, 9(5), 457. (doi: 10.1001/jamacardio.2024.0284) (PMID:38536153)

Buendia, Ruben, Karpefors, Martin, Folkvaljon, Folke, Hunter, Robert, Sillen, Henrik, Luu, Long, Docherty, Kieran ORCID: https://orcid.org/0000-0002-5446-9969 and Cowie, Martin R.(2024)Wearable sensors to monitor physical activity in heart failure clinical trials: state-of-the-art review. Journal of Cardiac Failure, 30(5), pp. 703-716. (doi: 10.1016/j.cardfail.2024.01.016) (PMID:38452999)

McMurray, J. J.V. et al. (2024)Effect of Dapagliflozin Versus Placebo on Symptoms and 6-Minute Walk Distance in Patients With Heart Failure: The DETERMINE Randomized Clinical Trials. Circulation, 149(11), pp. 825-838. (doi: 10.1161/CIRCULATIONAHA.123.065061) (PMID:38059368)

Brum, Wagner S., Docherty, Kieran F. ORCID: https://orcid.org/0000-0002-5446-9969, Ashton, Nicholas J., Zetterberg, Henrik, Hansson, Oskar, McMurray, John J. V. ORCID: https://orcid.org/0000-0002-6317-3975 and Blennow, Kaj(2024)Effect of neprilysin inhibition on Alzheimer disease plasma biomarkers: a secondary analysis of a randomized clinical trial. JAMA Neurology, 81(2), pp. 197-200. (doi: 10.1001/jamaneurol.2023.4719) (PMID:38109077) (PMCID:PMC10728797)

Docherty, K. F. et al. (2024)The effect of omecamtiv mecarbil in hospitalized patients as compared with outpatients with HFrEF: an analysis of GALACTIC-HF. Journal of Cardiac Failure, 30(1), pp. 26-35. (doi: 10.1016/j.cardfail.2023.08.020) (PMID:37683911)

Osmanska, J. et al. (2024)A novel, small-volume subcutaneous furosemide formulation delivered by an abdominal patch infusor device in patients with heart failure: results of two phase I studies. European Heart Journal: Cardiovascular Pharmacotherapy, 10, pp. 35-44. (doi: 10.1093/ehjcvp/pvad073) (PMID:37804170) (PMCID:PMC10766906)

2023

Kondo, T. et al. (2023)Efficacy of dapagliflozin according to heart rate: A patient-level pooled analysis of DAPA-HF and DELIVER. Circulation: Heart Failure, 16(12), e010898. (doi: 10.1161/CIRCHEARTFAILURE.123.010898) (PMID:37886880)

Matsumoto, S. et al. (2023)Calcium channel blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction. European Journal of Heart Failure, 25(12), pp. 2202-2214. (doi: 10.1002/ejhf.3044) (PMID:37771260)

Chatur, S. et al. (2023)Outpatient worsening among patients with mildly reduced and preserved ejection fraction heart failure in the DELIVER trial. Circulation, 148(22), pp. 1735-1745. (doi: 10.1161/circulationaha.123.066506) (PMID:37632455) (PMCID:PMC10664793)

Mc Causland, F. R. et al. (2023)Decline in estimated glomerular filtration rate after dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: A prespecified secondary analysis of the DELIVER randomized clinical trial. JAMA Cardiology, 9(2), pp. 144-152. (doi: 10.1001/jamacardio.2023.4664) (PMID:37952176) (PMCID:PMC10641768)

Docherty, Kieran F. ORCID: https://orcid.org/0000-0002-5446-9969(2023)SGLT2 inhibitors and iron: more than meets the eye. JACC: Heart Failure, 11(11), pp. 1623-1625. (doi: 10.1016/j.jchf.2023.08.013) (PMID:37737759)

Heerspink, H. J. L. et al. (2023)Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: a joint analysis of randomized controlled clinical trials. Diabetes, Obesity and Metabolism, 25(11), pp. 3327-3336. (doi: 10.1111/dom.15232) (PMID:37580309)

Butt, J. et al. (2023)Dapagliflozin and physical and social activity limitations in heart failure with reduced ejection fraction. JACC: Heart Failure, 11(10), pp. 1411-1423. (doi: 10.1016/j.jchf.2023.04.016) (PMID:37318419)

Lam, Carolyn S.P., Docherty, Kieran F. ORCID: https://orcid.org/0000-0002-5446-9969, Ho, Jennifer E., McMurray, John J.V. ORCID: https://orcid.org/0000-0002-6317-3975, Myhre, Peder L. and Omland, Torbjørn(2023)Recent successes in heart failure treatment. Nature Medicine, 29(10), pp. 2424-2437. (doi: 10.1038/s41591-023-02567-2) (PMID:37814060)

Yeoh, S. E. et al. (2023)Dapagliflozin versus metolazone in heart failure resistant to loop diuretics. European Heart Journal, 44(31), pp. 2966-2977. (doi: 10.1093/eurheartj/ehad341) (PMID:37210742)

Chatur, S. et al. (2023)Effects of dapagliflozin on heart failure hospitalizations according to severity of inpatient course: insights from DELIVER and DAPA-HF. European Journal of Heart Failure, 25(8), pp. 1364-1371. (doi: 10.1002/ejhf.2912) (PMID:37210608)

Docherty, Kieran F. ORCID: https://orcid.org/0000-0002-5446-9969, Jackson, Alice M., Macartney, Mark, Campbell, Ross T. ORCID: https://orcid.org/0000-0002-0050-2129, Petrie, Mark C. ORCID: https://orcid.org/0000-0002-6333-9496, Pfeffer, Marc A., McMurray, John J.V. ORCID: https://orcid.org/0000-0002-6317-3975 and Jhund, Pardeep S. ORCID: https://orcid.org/0000-0003-4306-5317(2023)Declining risk of heart failure hospitalization following first acute myocardial infarction in Scotland between 1991–2016. European Journal of Heart Failure, 25(8), pp. 1213-1224. (doi: 10.1002/ejhf.2965) (PMID:37401485)

Docherty, Kieran F. ORCID: https://orcid.org/0000-0002-5446-9969, Lam, Carolyn S.P., Rakisheva, Amina, Coats, Andrew J.S., Greenhalgh, Trisha, Metra, Marco, Petrie, Mark C. ORCID: https://orcid.org/0000-0002-6333-9496 and Rosano, Giuseppe M.C.(2023)Heart failure diagnosis in the general community - who, how and when? A clinical consensus statement of the Heart Failure Association (HFA) of the ESC. European Journal of Heart Failure, 25(8), pp. 1185-1198. (doi: 10.1002/ejhf.2946) (PMID:37368511)

Docherty, K. F. et al. (2023)Association of carbohydrate antigen 125 on the response to dapagliflozin in patients with heart failure. Journal of the American College of Cardiology, 82(2), pp. 142-157. (doi: 10.1016/j.jacc.2023.05.011) (PMID:37407113)

Curtain, J. P. et al. (2023)Prevalent and incident anemia in PARADIGM-HF and the effect of sacubitril/valsartan. JACC: Heart Failure, 11(7), pp. 749-759. (doi: 10.1016/j.jchf.2022.12.012) (PMID:37407154)

Talha, K. M. et al. (2023)Potential global impact of sodium‐glucose cotransporter‐2 inhibitors in heart failure. European Journal of Heart Failure, 25(7), pp. 999-1009. (doi: 10.1002/ejhf.2864) (PMID:37062865)

Butt, J. H. et al. (2023)Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER. European Heart Journal, 44(24), pp. 2170-2183. (doi: 10.1093/eurheartj/ehad276) (PMID:37220172) (PMCID:PMC10290876)

Campbell, Ross T. ORCID: https://orcid.org/0000-0002-0050-2129 and Docherty, Kieran F. ORCID: https://orcid.org/0000-0002-5446-9969(2023)Serum bicarbonate and congestion: a potential biomarker for identifying and guiding management in diuretic resistance? European Heart Journal, 44(22), pp. 2006-2008. (doi: 10.1093/eurheartj/ehad209) (PMID:37160825)

Yeoh, S. E. et al. (2023)Endothelin-1, outcomes in patients with heart failure and reduced ejection fraction, and effects of dapagliflozin: findings from DAPA-HF. Circulation, 147(22), pp. 1670-1683. (doi: 10.1161/CIRCULATIONAHA.122.063327) (PMID:37039015) (PMCID:PMC10212584)

Butt, J. H. et al. (2023)Dapagliflozin in Black and White patients with heart failure across the ejection fraction spectrum. JACC: Heart Failure, 11(4), pp. 375-388. (doi: 10.1016/j.jchf.2022.11.014) (PMID:36881399)

Butt, J. H. et al. (2023)Association of dapagliflozin use with clinical outcomes and the introduction of uric acid–lowering therapy and colchicine in patients with heart failure with and without gout. JAMA Cardiology, 8(4), pp. 386-393. (doi: 10.1001/jamacardio.2022.5608) (PMID:36811901) (PMCID:PMC9947801)

Adamson, C. et al. (2023)IGFBP-7 and outcomes in heart failure with reduced ejection fraction: findings from DAPA-HF. JACC: Heart Failure, 11(3), pp. 291-304. (doi: 10.1016/j.jchf.2022.09.004) (PMID:36592046)

Docherty, Kieran F. ORCID: https://orcid.org/0000-0002-5446-9969 and Jhund, Pardeep S. ORCID: https://orcid.org/0000-0003-4306-5317(2023)A welcome ‘failure’ of gliflozins: blood pressure reduction in heart failure. European Heart Journal, 44(5), pp. 408-410. (doi: 10.1093/eurheartj/ehac712) (PMID:36514970)

Docherty, K. F. et al. (2023)Efficacy of omecamtiv mecarbil in heart failure with reduced ejection fraction according to N‐terminal pro‐B ‐type natriuretic peptide level: insights from the GALACTIC‐HF trial. European Journal of Heart Failure, 25(2), pp. 248-259. (doi: 10.1002/ejhf.2763) (PMID:36597719)

Lee, Matthew M.Y. ORCID: https://orcid.org/0000-0001-9213-2067, Campbell, Ross T. ORCID: https://orcid.org/0000-0002-0050-2129, Claggett, Brian L., Lewis, Eldrin F., Docherty, Kieran F. ORCID: https://orcid.org/0000-0002-5446-9969, Lindner, Moritz, Liu, Jiankang, Solomon, Scott D., McMurray, John J.V. ORCID: https://orcid.org/0000-0002-6317-3975 and Platz, Elke(2023)Health‐related quality of life in acute heart failure: association between patient‐reported symptoms and markers of congestion. European Journal of Heart Failure, 25(1), pp. 54-60. (doi: 10.1002/ejhf.2699) (PMID:36161429) (PMCID:PMC9892176)

Mc Causland, F. R. et al. (2023)Dapagliflozin and kidney outcomes in patients with heart failure with mildly reduced or preserved ejection fraction. JAMA Cardiology, 8(1), pp. 56-65. (doi: 10.1001/jamacardio.2022.4210) (PMID:36326604)

2022

Yang, M. et al. (2022)Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartan. European Journal of Heart Failure, 24(12), pp. 2307-2319. (doi: 10.1002/ejhf.2722) (PMID:36342375)

Sun, G. et al. (2022)Gender- and age-specific rates of heart failure and other adverse cardiovascular outcomes in systemic sclerosis. Rheumatology, 61(11), pp. 4374-4383. (doi: 10.1093/rheumatology/keac072) (PMID:35136973)

Ferreira, João Pedro, Claggett, Brian L., Docherty, Kieran F. ORCID: https://orcid.org/0000-0002-5446-9969, Jhund, Pardeep S. ORCID: https://orcid.org/0000-0003-4306-5317, Zannad, Faiez, Solomon, Scott D. and McMurray, John J.V. ORCID: https://orcid.org/0000-0002-6317-3975(2022)Within trial comparison of survival time projections from short-term follow-up with long-term follow-up findings. ESC Heart Failure, 9(5), pp. 3655-3658. (doi: 10.1002/ehf2.13731) (PMID:35799450) (PMCID:PMC9715817)

Docherty, K. F. et al. (2022)Iron deficiency in heart failure and effect of dapagliflozin: findings from DAPA-HF. Circulation, 146(13), pp. 980-994. (doi: 10.1161/CIRCULATIONAHA.122.060511) (PMID:35971840) (PMCID:PMC9508991)

Vaduganathan, M. et al. (2022)SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet, 400(10354), pp. 757-767. (doi: 10.1016/S0140-6736(22)01429-5) (PMID:36041474)

Jhund, P. S. et al. (2022)Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER. Nature Medicine, 28(9), pp. 1956-1964. (doi: 10.1038/s41591-022-01971-4) (PMID:36030328) (PMCID:PMC9499855)

Adamson, C. et al. (2022)Initial decline ("dip") in estimated glomerular filtration rate following initiation of dapagliflozin in patients with heart failure and reduced ejection fraction: insights from DAPA-HF. Circulation, 146(6), pp. 438-449. (doi: 10.1161/CIRCULATIONAHA.121.058910) (PMID:35442064) (PMCID:PMC9354593)

Butt, J. H. et al. (2022)Effects of dapagliflozin according to the heart failure collaboratory medical therapy score insights from DAPA-HF. JACC: Heart Failure, 10(8), pp. 543-555. (doi: 10.1016/j.jchf.2022.03.009) (PMID:35902157)

Lee, M. M.Y. et al. (2022)Effect of empagliflozin on kidney biochemical and imaging outcomes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation, 146(4), pp. 364-367. (doi: 10.1161/CIRCULATIONAHA.122.059851) (PMID:35877829)

Lewis, G. D. et al. (2022)Effect of omecamtiv mecarbil on exercise capacity in chronic heart failure with reduced ejection fraction. JAMA: Journal of the American Medical Association, 328(3), pp. 259-269. (doi: 10.1001/jama.2022.11016) (PMID:35852527)

Shen, L. et al. (2022)Accelerated and personalized therapy for heart failure with reduced ejection fraction. European Heart Journal, 43(27), pp. 2573-2587. (doi: 10.1093/eurheartj/ehac210) (PMID:35467706)

McDowell, Kirsty and Docherty, Kieran F. ORCID: https://orcid.org/0000-0002-5446-9969(2022)Sodium-glucose cotransporter 2 inhibitors: the first universal treatment for heart failure? European Heart Journal: Quality of Care and Clinical Outcomes, 8(4), pp. 371-373. (doi: 10.1093/ehjqcco/qcab088) (PMID:34921601) (PMCID:PMC9170565)

Butt, J. H. et al. (2022)Efficacy and safety of dapagliflozin according to frailty in heart failure with reduced ejection fraction. Annals of Internal Medicine, 175(6), pp. 820-830. (doi: 10.7326/m21-4776) (PMID:35467935)

McDowell, K. et al. (2022)Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HF. European Journal of Heart Failure, 24(6), pp. 1066-1076. (doi: 10.1002/ejhf.2433) (PMID:35064721)

McMurray, John J.V. ORCID: https://orcid.org/0000-0002-6317-3975 and Docherty, Kieran F. ORCID: https://orcid.org/0000-0002-5446-9969(2022)Insights into foundational therapies for heart failure with reduced ejection fraction. Clinical Cardiology, 45(S1), S26-S30. (doi: 10.1002/clc.23847) (PMID:35789017) (PMCID:PMC9254667)

Butt, Jawad H., Adamson, Carly, Docherty, Kieran F. ORCID: https://orcid.org/0000-0002-5446-9969, Vaduganathan, Muthiah, Solomon, Scott D., Anand, Inder S., Zannad, Faiez, Køber, Lars, Jhund, Pardeep S. ORCID: https://orcid.org/0000-0003-4306-5317 and McMurray, John J.V. ORCID: https://orcid.org/0000-0002-6317-3975(2022)Eligibility for pharmacological therapies in heart failure with reduced ejection fraction: implications of the new CKD-EPI creatinine equation for estimating glomerular filtration rate. European Journal of Heart Failure, 24(5), pp. 861-866. (doi: 10.1002/ejhf.2460) (PMID:35199418)

Jhund, Pardeep S. ORCID: https://orcid.org/0000-0003-4306-5317, Docherty, Kieran F. ORCID: https://orcid.org/0000-0002-5446-9969 and McMurray, John J.V. ORCID: https://orcid.org/0000-0002-6317-3975(2022)Age-adjusted survival extrapolations—results may differ from those generated by the Weibull model—reply. JAMA Cardiology, 7(5), p. 570. (doi: 10.1001/jamacardio.2021.6032) (PMID:35234820)

Lee, Matthew M.Y. ORCID: https://orcid.org/0000-0001-9213-2067, Docherty, Kieran F. ORCID: https://orcid.org/0000-0002-5446-9969 and Jhund, Pardeep S. ORCID: https://orcid.org/0000-0003-4306-5317(2022)Sodium–glucose co-transporter-2 inhibitors. In: Clark, Andrew L., Gardner, Roy S. and McDonagh, Theresa A. (eds.)Oxford Textbook of Heart Failure (2 edn). Oxford University Press, pp. 637-644. ISBN 9780198766223(doi: 10.1093/med/9780198766223.003.0051)

Lewis, G. D. et al. (2022)Developments in exercise capacity assessment in heart failure clinical trials and the rationale for the design of METEORIC-HF. Circulation: Heart Failure, 15(5), e008970. (doi: 10.1161/CIRCHEARTFAILURE.121.008970) (PMID:35236099)

Yeoh, S. E. et al. (2022)Relationship of dapagliflozin with serum sodium: findings from the DAPA-HF trial. JACC: Heart Failure, 10(5), pp. 306-318. (doi: 10.1016/j.jchf.2022.01.019) (PMID:35483792)

Docherty, K. F. et al. (2022)Effects of dapagliflozin in Asian patients with heart failure and reduced ejection fraction in DAPA-HF. JACC: Asia, 2(2), pp. 139-153. (doi: 10.1016/j.jacasi.2022.02.004) (PMID:36339117) (PMCID:PMC9627879)

Butt, J. H. et al. (2022)Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF. European Journal of Heart Failure, 24(3), pp. 513-525. (doi: 10.1002/ejhf.2381) (PMID:34766424)

Curtain, J. P. et al. (2022)Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in PARADIGM-HF. European Journal of Heart Failure, 24(3), pp. 551-561. (doi: 10.1002/ejhf.2419) (PMID:34969175)

Lee, M. M.Y. et al. (2022)Renin–angiotensin system blockers, risk of SARS-CoV-2 infection and outcomes from CoViD-19: systematic review and meta-analysis. European Heart Journal: Cardiovascular Pharmacotherapy, 8(2), pp. 165-178. (doi: 10.1093/ehjcvp/pvaa138) (PMID:33337478) (PMCID:PMC7799280)

Docherty, Kieran F. ORCID: https://orcid.org/0000-0002-5446-9969 and Petrie, Mark C. ORCID: https://orcid.org/0000-0002-6333-9496(2022)Sodium-glucose cotransporter 2 inhibitors as a treatment for heart failure. Heart, 108(4), pp. 312-320. (doi: 10.1136/heartjnl-2020-318658) (PMID:34127540)

Berg, D. D. et al. (2022)Serial assessment of high-sensitivity cardiac troponin and the effect of dapagliflozin in patients with heart failure with reduced ejection fraction: an analysis of the DAPA-HF trial. Circulation, 145(3), pp. 158-169. (doi: 10.1161/CIRCULATIONAHA.121.057852) (PMID:34743554)

Rossing, P. et al. (2022)Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials. Lancet Diabetes and Endocrinology, 10(1), pp. 24-34. (doi: 10.1016/S2213-8587(21)00295-3) (PMID:34856173)

2021

Butt, J. H. et al. (2021)Efficacy and safety of dapagliflozin in heart failure with reduced ejection fraction according to N-terminal pro-B-type natriuretic peptide: insights from the DAPA-HF trial. Circulation: Heart Failure, 14(12), e008837. (doi: 10.1161/CIRCHEARTFAILURE.121.008837) (PMID:34802253)

Docherty, K. F. et al. (2021)Extrapolating long-term event-free and overall survival with dapagliflozin in patients with heart failure and reduced ejection fraction: an exploratory analysis of a phase 3 randomized clinical trial. JAMA Cardiology, 6(11), pp. 1298-1305. (doi: 10.1001/jamacardio.2021.2632) (PMID:34319398)

Lee, M. et al. (2021)Lung Ultrasound in Acute Heart Failure: Association Between Quality of Life, Symptoms and B-Lines. ESC Congress, 27-30 Aug 2021.(doi: 10.1093/eurheartj/ehab724.1043)

Adamson, C. et al. (2021)Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index. European Journal of Heart Failure, 23(10), pp. 1662-1672. (doi: 10.1002/ejhf.2308) (PMID:34272791)

Petrie, Mark C. ORCID: https://orcid.org/0000-0002-6333-9496, Lee, Matthew M.Y. ORCID: https://orcid.org/0000-0001-9213-2067 and Docherty, Kieran F. ORCID: https://orcid.org/0000-0002-5446-9969(2021)Sodium–glucose co-transporter 2 inhibitors—the first successful treatment for heart failure with preserved ejection fraction? European Journal of Heart Failure, 23(8), pp. 1256-1259. (doi: 10.1002/ejhf.2108) (PMID:33502794)

Curtain, J. P. et al. (2021)Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. European Heart Journal, 42(36), pp. 3727-3738. (doi: 10.1093/eurheartj/ehab560) (PMID:34448003) (PMCID:PMC8455345)

Docherty, K. F. et al. (2021)The effect of neprilysin inhibition on left ventricular remodeling in patients with asymptomatic left ventricular systolic dysfunction late after myocardial infarction. Circulation, 144(3), pp. 199-209. (doi: 10.1161/CIRCULATIONAHA.121.054892) (PMID:33983794)

Butt, J. H. et al. (2021)Efficacy and safety of dapagliflozin in men and women with heart failure with reduced ejection fraction: results from the DAPA-HF trial. JAMA Cardiology, 6(6), pp. 678-689. (doi: 10.1001/jamacardio.2021.0379) (PMID:33787831)

Espersen, C. et al. (2021)Sex differences in congestive markers in patients hospitalized for acute heart failure. ESC Heart Failure, 8(3), pp. 1784-1795. (doi: 10.1002/ehf2.13300) (PMID:33709520) (PMCID:PMC8120385)

Jhund, P. S. et al. (2021)Dapagliflozin and recurrent heart failure hospitalizations in heart failure with reduced ejection fraction: an analysis of DAPA-HF. Circulation, 143(20), pp. 1962-1972. (doi: 10.1161/CIRCULATIONAHA.121.053659) (PMID:33832352) (PMCID:PMC8126492)

Berg, D. D. et al. (2021)Time to clinical benefit of dapagliflozin and significance of prior heart failure hospitalization in patients with heart failure with reduced ejection fraction. JAMA Cardiology, 6(5), pp. 499-507. (doi: 10.1001/jamacardio.2020.7585) (PMID:33595593)

McMurray, John J.V. ORCID: https://orcid.org/0000-0002-6317-3975, Solomon, Scott D., Docherty, Kieran F. ORCID: https://orcid.org/0000-0002-5446-9969 and Jhund, Pardeep S. ORCID: https://orcid.org/0000-0003-4306-5317(2021)The Dapagliflozin And Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF) in context. European Heart Journal, 42(13), pp. 1199-1202. (doi: 10.1093/eurheartj/ehz916) (PMID:31898736) (PMCID:PMC8014512)

Butt, J. H. et al. (2021)Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial. European Journal of Heart Failure, 23(4), pp. 601-613. (doi: 10.1002/ejhf.2124) (PMID:33594755)

Dewan, P. et al. (2021)Effects of dapagliflozin in heart failure with reduced ejection fraction, and chronic obstructive pulmonary disease: an analysis of DAPA-HF. European Journal of Heart Failure, 23(4), pp. 632-643. (doi: 10.1002/ejhf.2083) (PMID:33368858) (PMCID:PMC8247863)

Docherty, K. F. et al. (2021)Effect of dapagliflozin on anaemia in DAPA-HF. European Journal of Heart Failure, 23(4), pp. 617-628. (doi: 10.1002/ejhf.2132) (PMID:33615642)

Lee, M. M.Y. et al. (2021)Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation, 143(6), pp. 516-525. (doi: 10.1161/CIRCULATIONAHA.120.052186) (PMID:33186500) (PMCID:PMC7864599)

Docherty, K. F. et al. (2021)Rationale and methods of a randomized trial evaluating the effect of neprilysin inhibition on left ventricular remodelling. ESC Heart Failure, 8(1), pp. 129-138. (doi: 10.1002/ehf2.13137) (PMID:33305513) (PMCID:PMC7835504)

Inzucchi, S. E. et al. (2021)Dapagliflozin and the incidence of type 2 diabetes in patients with heart failure and reduced ejection fraction: an exploratory analysis from DAPA-HF. Diabetes Care, 44(2), pp. 586-594. (doi: 10.2337/dc20-1675) (PMID:33355302)

Jhund, P. S. et al. (2021)Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF. Circulation, 143(4), pp. 289-309. (doi: 10.1161/CIRCULATIONAHA.120.050391) (PMID:33040613) (PMCID:PMC7834909)

Docherty, Kieran F. ORCID: https://orcid.org/0000-0002-5446-9969 and Vaduganathan, Muthiah(2021)OUTSTEP‐HF: re‐evaluating the role of physical activity measures in drug and device development in heart failure. European Journal of Heart Failure, 23(1), pp. 136-139. (doi: 10.1002/ejhf.2106) (PMID:33480140)

McMurray, John J.V. ORCID: https://orcid.org/0000-0002-6317-3975 and Docherty, Kieran F. ORCID: https://orcid.org/0000-0002-5446-9969(2021)SOLOIST-WHF: Sodium-glucose cotransporter 2 (SGLT2) inhibitors should be initiated in patients hospitalised with worsening heart failure. European Journal of Heart Failure, 23(1), pp. 27-30. (doi: 10.1002/ejhf.2075) (PMID:33283384)

2020

Ferreira, J. P. et al. (2020)Estimating the lifetime benefits of treatments for heart failure. JACC: Heart Failure, 8(12), pp. 984-995. (doi: 10.1016/j.jchf.2020.08.004) (PMID:33039448) (PMCID:PMC7720789)

Kristensen, S. L. et al. (2020)Prevalence and incidence of intra-ventricular conduction delays and outcomes in patients with heart failure and reduced ejection fraction: insights from PARADIGM‐HF and ATMOSPHERE. European Journal of Heart Failure, 22(12), pp. 2370-2379. (doi: 10.1002/ejhf.1972) (PMID:32720404)

Docherty, K. et al. (2020)Effect of dapagliflozin in DAPA-HF according to background glucose-lowering therapy. Diabetes Care, 43(11), pp. 2878-2881. (doi: 10.2337/dc20-1402) (PMID:33082245)

McEwan, Phil, Darlington, Oliver, McMurray, John J.V. ORCID: https://orcid.org/0000-0002-6317-3975, Jhund, Pardeep S. ORCID: https://orcid.org/0000-0003-4306-5317, Docherty, Kieran F. ORCID: https://orcid.org/0000-0002-5446-9969, Böhm, Michael, Petrie, Mark C. ORCID: https://orcid.org/0000-0002-6333-9496, Bergenheim, Klas and Qin, Lei(2020)Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of DAPA-HF. European Journal of Heart Failure, 22(11), pp. 2147-2156. (doi: 10.1002/ejhf.1978) (PMID:32749733) (PMCID:PMC7756637)

Docherty, K. F. et al. (2020)Effect of dapagliflozin on outpatient worsening of patients with heart failure and reduced ejection fraction: a prespecified analysis of DAPA-HF. Circulation, 142(17), pp. 1623-1632. (doi: 10.1161/CIRCULATIONAHA.120.047480) (PMID:32883108) (PMCID:PMC7580857)

Docherty, Kieran F. ORCID: https://orcid.org/0000-0002-5446-9969, Vaduganathan, Muthiah, Solomon, Scott D. and McMurray, John J.V. ORCID: https://orcid.org/0000-0002-6317-3975(2020)Sacubitril/valsartan: neprilysin inhibition 5 Years after PARADIGM-HF. JACC: Heart Failure, 8(10), pp. 800-810. (doi: 10.1016/j.jchf.2020.06.020)

Serenelli, M. et al. (2020)Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). European Heart Journal, 41(36), pp. 3402-3418. (doi: 10.1093/eurheartj/ehaa496) (PMID:32820334) (PMCID:PMC7550197)

Jackson, A. M. et al. (2020)Dapagliflozin and diuretic use in patients with heart failure and reduced ejection fraction in DAPA-HF. Circulation, 142(11), pp. 1040-1054. (doi: 10.1161/CIRCULATIONAHA.120.047077) (PMID:32673497) (PMCID:PMC7664959)

Docherty, K. F. et al. (2020)Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. European Heart Journal, 41(25), pp. 2379-2392. (doi: 10.1093/eurheartj/ehaa183) (PMID:32221582) (PMCID:PMC7327533)

Docherty, K. F. et al. (2020)Predictors of sudden cardiac death in high-risk patients following a myocardial infarction. European Journal of Heart Failure, 22(5), pp. 848-855. (doi: 10.1002/ejhf.1694) (PMID:31944496)

Petrie, M. C., et al. (2020)Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. JAMA: Journal of the American Medical Association, 323(14), pp. 1353-1368. (doi: 10.1001/jama.2020.1906) (PMID:32219386) (PMCID:PMC7157181)

Docherty, K. F. et al. (2020)Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction. European Journal of Heart Failure, 22(3), pp. 528-538. (doi: 10.1002/ejhf.1682) (PMID:31849164)

Kosiborod, M. N. et al. (2020)Effects of dapagliflozin on symptoms, function and quality of life in patients with heart failure and reduced ejection fraction: results from the DAPA-HF trial. Circulation, 141(2), pp. 90-99. (doi: 10.1161/CIRCULATIONAHA.119.044138) (PMID:31736335) (PMCID:PMC6964869)

2019

McMurray, J. J.V. et al. (2019)Dapagliflozin in patients with heart failure and reduced ejection fraction. New England Journal of Medicine, 381, pp. 1995-2008. (doi: 10.1056/NEJMoa1911303)

Docherty, Kieran F. ORCID: https://orcid.org/0000-0002-5446-9969 and McMurray, John J.V. ORCID: https://orcid.org/0000-0002-6317-3975(2019)PIONEER-HF: a new frontier in the role of neprilysin inhibition in the management of heart failure with reduced ejection fraction. Cardiovascular Research, 115(13), e136-e139. (doi: 10.1093/cvr/cvz223) (PMID:31497841)

Platz, E. et al. (2019)Lung ultrasound in acute heart failure: prevalence of pulmonary congestion and short- and long-term outcomes. JACC: Heart Failure, 7(10), pp. 849-858. (doi: 10.1016/j.jchf.2019.07.008) (PMID:31582107)

Kristensen, Soren L., Rorth, Rasmus, Jhund, Pardeep S. ORCID: https://orcid.org/0000-0003-4306-5317, Docherty, Kieran ORCID: https://orcid.org/0000-0002-5446-9969, Sattar, Naveed ORCID: https://orcid.org/0000-0002-1604-2593, Preiss, David ORCID: https://orcid.org/0000-0003-3139-1836, Kober, Lars, Petrie, Mark C. ORCID: https://orcid.org/0000-0002-6333-9496 and McMurray, John J.V. ORCID: https://orcid.org/0000-0002-6317-3975(2019)Cardiovascular, mortality and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes and Endocrinology, 7(10), pp. 776-785. (doi: 10.1016/S2213-8587(19)30249-9) (PMID:31422062)

McMurray, John J.V. ORCID: https://orcid.org/0000-0002-6317-3975 and Docherty, Kieran F. ORCID: https://orcid.org/0000-0002-5446-9969(2019)Phosphodiesterase-9 inhibition in heart failure: a further opportunity to augment the effects of natriuretic peptides? Journal of the American College of Cardiology, 74(7), pp. 902-904. (doi: 10.1016/j.jacc.2019.07.008) (PMID:31416534)

Dewan, Pooja ORCID: https://orcid.org/0000-0003-2927-4075, Docherty, Kieran F. ORCID: https://orcid.org/0000-0002-5446-9969 and McMurray, John J.V. ORCID: https://orcid.org/0000-0002-6317-3975(2019)Sacubitril/valsartan in Asian patients with heart failure with reduced ejection fraction. Korean Circulation Journal, 49(6), pp. 469-484. (doi: 10.4070/kcj.2019.0136) (PMID:31172710) (PMCID:PMC6554586)

Shen, L. et al. (2019)Prior pacemaker implantation and clinical outcomes in patients with heart failure and preserved ejection fraction. JACC: Heart Failure, 7(5), pp. 418-427. (doi: 10.1016/j.jchf.2018.12.006) (PMID:30981744)

Docherty, Kieran F. ORCID: https://orcid.org/0000-0002-5446-9969 and McMurray, John J.V. ORCID: https://orcid.org/0000-0002-6317-3975(2019)Angiotensin receptor-neprilysin inhibitors: a new paradigm in heart failure with reduced ejection fraction. International Journal of Cardiology, 281, pp. 179-185. (doi: 10.1016/j.ijcard.2018.05.124) (PMID:29891240)

2018

Docherty, Kieran F. ORCID: https://orcid.org/0000-0002-5446-9969 and Jhund, Pardeep S. ORCID: https://orcid.org/0000-0003-4306-5317(2018)Early use of mineralocorticoid receptor antagonists in ST-elevation myocardial infarction: is it ever too early? Heart, 104(22), pp. 1812-1813. (doi: 10.1136/heartjnl-2018-313371) (PMID:29760244)

Docherty, Kieran F. ORCID: https://orcid.org/0000-0002-5446-9969, Jhund, Pardeep S. ORCID: https://orcid.org/0000-0003-4306-5317 and McMurray, John J.V. ORCID: https://orcid.org/0000-0002-6317-3975(2018)Catheter ablation for atrial fibrillation with heart failure. New England Journal of Medicine, 379(5), pp. 491-492. (doi: 10.1056/NEJMc1806519) (PMID:30070094)

2017

Docherty, Kieran F. ORCID: https://orcid.org/0000-0002-5446-9969, Campbell, Ross T. ORCID: https://orcid.org/0000-0002-0050-2129, Jhund, Pardeep ORCID: https://orcid.org/0000-0003-4306-5317, Petrie, Mark C. ORCID: https://orcid.org/0000-0002-6333-9496 and McMurray, John J.V. ORCID: https://orcid.org/0000-0002-6317-3975(2017)How robust are clinical trials in heart failure? European Heart Journal, 38(5), pp. 338-345. (doi: 10.1093/eurheartj/ehw427) (PMID:27742808)

2016

Wilson, Matthew R. ORCID: https://orcid.org/0000-0001-5423-3270, Docherty, Kieran F. ORCID: https://orcid.org/0000-0002-5446-9969 and Gardner, Roy S.(2016)Use of direct oral anticoagulants in thromboembolic disease. Prescriber, 27(8), pp. 15-22. (doi: 10.1002/psb.1487)

2014

Docherty, Kieran F. ORCID: https://orcid.org/0000-0002-5446-9969 and Padmanabhan, Sandosh ORCID: https://orcid.org/0000-0003-3869-5808(2014)Genomics and pharmacogenomics of lipid-lowering therapies. In: Padmanabhan, Sandosh (ed.)Handbook of Pharmacogenomics and Stratified Medicine. Academic Press: London, pp. 715-746. ISBN 9780123868831(doi: 10.1016/B978-0-12-386882-4.00031-1)

2013

Vuorio, A., Docherty, K.F. ORCID: https://orcid.org/0000-0002-5446-9969, Humphries, S.E., Kuoppala, J. and Kovanen, P.T.(2013)Statin treatment of children with familial hypercholesterolemia – trying to balance incomplete evidence of long-term safety and clinical accountability: are we approaching a consensus? Atherosclerosis, 226(2), pp. 315-320. (doi: 10.1016/j.atherosclerosis.2012.10.032)

This list was generated on Mon Feb 16 09:40:22 2026 GMT.